Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease

Journal of Immunology

Volumn 164, Issue 10, 2000, Pages 5015-5018

  Oaks, Martin K ^a   Hallett, Karen M ^b  

^a ST LUKE S MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; ANIMAL CELL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOREACTIVITY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; THYROID DISEASE;

EID: 0034657891     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.10.5015     Document Type: Article

References (27)

1. Brunet, J. F., F. Denizot, M. F. Luciani, M. Roux-Dosseto, M. Suzan, M. G. Mattei, and P. Golstein. 1987. A new member of the immunoglobulin superfamily: CTLA-4. Nature 328:267.
2. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, and J. A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173:721.
3. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174:561.
4. Thompson, C. B., and J. P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity 7:445.
5. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270: 985.
6. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541.
7. Karandikar, N. J., C. L. Vanderlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone. 1996. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184:783.
8. Luhder, F., P. Hoglund, J. P. Allison, C. Benoist, and D. Mathis. 1998. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune disease. J. Exp. Med. 187:427.
9. Yanagawa, T., Y. Hidaka, V. Guimaraes, M. Soliman, and L. J. DeGroot. 1995. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J. Clin. Endocrinol. Metab. 80:41.
10. Nistico, L., R. Buzzetti, L. E. Pritchard, B. Van der Auwera, C. Giovannini, E. Bosi, M. T. Larrad, M. S. Rios, C. C. Chow, C. S. Cockram, et al. 1996. The CTLA-4 gene region of chromosome 2q33 is linked to and associated with type 1 diabetes. Hum. Mol. Genet. 5:1075.
11. Donner, H., H. Rau, P. G. Walfish, J. Braun, T. Siegmund, R. Finke, J. Herwig, K. H. Usadel, and K. Badenhoop. 1997. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 82:143.
12. Marron, M. P., L. J. Raffel, H. Garchon, C. O. Jacob, M. Serrano-Rios, M. T. Martinez Larrad, W. P. Teng, Y. Park, Z. X. Zhang, D. R. Goldstein, et al. 1997. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum. Mol. Genet. 6:1275.
13. Kosta, K., P. F. Watson, and A. P. Weetman. 1997. A CTLA-4 gene polymorphism is associated with both Graves' disease and autoimmune hypothyroidism. Clin. Endocrinol. 46:551.
14. Kemp, E. H., R. A. Ajjan, E. S. Husebye, P. Peterson, R. Uibo, H. Imrie, S. H. Pearce, P. F. Watson, and A. P. Weetman. 1998. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addisons' disease in English patients. Clin. Endocrinol. 49:609.
15. Van Der Auwera, B. J., C. L. Vandewalle, F. C. Schuit, F. Winnock, I. H. De Leeuw, S. Van Imschoot, G. Lamberigts, and F. K. Gorus. 1997. CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers: the Belgian diabetes registry. Clin. Exp. Immunol. 110:98.
16. Awata, T., S. Kurihara, M. Iitaka, S. Takei, I. Inoue, C. Ishii, K. Negishi, T. Izumida, Y. Yoshida, R. Hagura, et al. 1998. Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population. Diabetes 47:128.
17. Heward, J. M., A. Allahabadia, M. Armitage, A. Hattersley, P. M. Dodson, K. Macleod, J. Carr-Smith, J. Daykin, A. Daly, M. C. Sheppard, et al. 1999. The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J. Clin. Endocrinol. Metab. 84:2398.
18. Magistrelli, G., P. Jeannin, N. Herbault, A. B. de Colgnac, J. F. Gauchat, J. Y. Bonnefoy, and Y. Delneste. 1999. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29:3596.
19. Harper, K., C. Balzano, E. Rouvier, M. G. Mattei, M. F. Luciani, and P. Golstein. 1991. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J. Immunol. 147:1037.
20. Schall, T. J., M. Lewis, K. J. Koller, A. Lee, G. C. Rice, G. H. Wong, T. Gatanaga, G. A. Granger, R. Lentz, H. Raab, 1991. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61:361.
21. Josimovic-Alasevic, O., T. Hermann, and T. Diamenstein. 1998. Demonstration of two distinct forms of released low-affinity type interleukin 2 receptors. Eur. J. Immunol. 18:1855.
22. Mosley, B., M. P. Beckmann, C. J. March, R. L. Idzerda, S. D. Gimpel, T. VandenBos, D. Friend, A. Alpert, D. Anderson, J. Jackson, et al. 1989. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 59:335.
23. Goodwin, R. G., D. Friend, S. F. Ziegler, R. Jerzy, B. A. Falk, S. Gimpel, D. Cosman, S. K. Dower, C. J. March, A. E. Namen, et al. 1990. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 60:941.
24. Cheng, J., T. Zhou, C. Liu, J. P. Shapiro, M. J. Brauer, M. C. Kiefer, P. J. Barr, and J. D. Mountz. 1994. Protection from Fas-mediated apoptosis by a soluble from of the Fas molecule. Science 263:1759.
25. Fernandez-Botran, R. 1991. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 5:2567.
26. Polymeropoulos, M. H., H. Xiao, D. S. Rath, and C. R. Merril. 1991. Dinucleotide repeat polymorphism at the human CTLA4 gene. Nucleic Acids Res. 19: 4018.
27. Shaw, G., and R. Kamen. 1986. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:659.